<?xml version="1.0"?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="0"/>
	</teiHeader>
	<text xml:lang="en">
			<front>Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/>https://doi.org/10.1007/s13369-020-04626-z <lb/>R E S E A R C H A R T I C L E -C H E M I S T R Y <lb/>Design, Synthesis, and Biological Evaluation <lb/>of 1,2,4-Thiadiazole-1,2,4-Triazole Derivatives Bearing Amide <lb/>Functionality as Anticancer Agents <lb/>Yazala Jyothsna Pragathi 1 • Reddymasu Sreenivasulu 2 • Deekala Veronica 1 • Rudraraju Ramesh Raju 1 <lb/>Received: 25 November 2019 / Accepted: 10 May 2020 / Published online: 22 May 2020 <lb/>© King Fahd University of Petroleum &amp; Minerals 2020 <lb/>Abstract <lb/>A novel library of amide functionality having 1,2,4-thiadiazole-1,2,4-triazole (8a-j) analogs was designed, synthesized, and <lb/>structures were characterized by 1 H NMR, 13 C NMR, and mass (ESI-MS) spectral data. Further, all compounds were evaluated <lb/>for their anticancer activities against four different cancer cell lines including breast cancer (MCF-7, MDA MB-231), lung <lb/>cancer (A549), and prostate cancer (DU-145) by MTT reduction assay method, and etoposide acts as a standard drug. The <lb/>results confirmed that majority of the synthesized compounds showed moderate to potent anticancer activities aligned with <lb/>four cell lines. Among the synthesized compounds, 8b, 8c, 8d, 8e, 8g and 8i displayed more potent activity along with <lb/>inhibitory concentration values ranging from 0.10 ± 0.084 to 11.5 ± 6.49 μM than the standard IC 50 values, which ranges <lb/>from 1.91 ± 0.84 to 3.08 ± 0.135 μM, respectively. <lb/>Keywords Letrozole • 3,5-Bis(pyridin-3-yl)-1,2,4-thiadiazole • 1,2,4-Triazole • 1,2,4-Thiadiazole • Anticancer activity <lb/></front>

			<body>1 Introduction <lb/>Cancer is very dangerous disease with uncontrolled growth <lb/>and rapid spreading of abnormal cells [1]. Several external <lb/>and internal factors are caused to abnormal growth of cell <lb/>lines and induced the different cancers [2-7]. Currently, three <lb/>types of treatment are available for cancer disease including <lb/>chemotherapy, radiotherapy, and surgery [8]. The standard <lb/>treatment for cancer patients is chemotherapy, in which dif-<lb/>ferent chemotherapeutic agents are used to kill the cancer <lb/>cells without any harmful effective on normal kidney cells <lb/>[9-13]. <lb/>Nitrogen atoms contain heterocyclic ring moieties that are <lb/>present both in natural products and in synthetic derivatives <lb/></body>

			<front>Electronic supplementary material The online version of this article <lb/>(https://doi.org/10.1007/s13369-020-04626-z) contains supplementary <lb/>material, which is available to authorized users. <lb/>B Rudraraju Ramesh Raju <lb/>rrraju1@gmail.com <lb/>1 <lb/>Department of Chemistry, Acharya Nagarjuna University, <lb/>Nagarjuna Nagar, Andhra Pradesh 522510, India <lb/>2 <lb/>Department of Chemistry, University College of Engineering <lb/>(Autonomous), Jawaharlal Nehru Technological <lb/>University, Kakinada, Andhra Pradesh 533 003, India <lb/></front>

			<body>and exhibited potent anticancer activities against different <lb/>human cancer cell lines [14-32]. Three nitrogen atoms con-<lb/>taining heterocyclic ring such as 1,2,4-triazoles play an <lb/>important critical role in the structural elucidation of various <lb/>natural products [33] and are able to form hydrogen bonding <lb/>with suitable targets leading to improving of pharmacokinet-<lb/>ics, pharmacological, and toxicological properties [34, 35]. <lb/>These 1,2,4-triazole derivatives are associated with different <lb/>pharmaceutical activities such as anticancer [36], antibacte-<lb/>rial [37], antitubercular [38], antifungal [39], antiviral [40], <lb/>analgesic [41], anti-inflammatory [42], and tubulin inhibitors <lb/>[43]. Letrozole (1, Fig. 1) [44, 45] is a triazole structural unit <lb/>containing aromatase inhibitor and is used for cancer treat-<lb/>ment. <lb/>Similarly, 1,2,4-thiadiazoles are considered as most sig-<lb/>nificant subclass of bioactive five-membered organic com-<lb/>pounds for medicinal chemistry [46] and showed a remark-<lb/>able biological activities such as cyclooxygenase inhibitors <lb/>[47], human leukemia [48], antibacterial [49], antiulcerative <lb/>[50], antihypertensive [51], cathepsin B inhibitors [52], anti-<lb/>convulsant [53], antidiabetic [54], anti-inflammatory [47], <lb/>and allosteric modulators [55]. One of the anticancer drug <lb/>scaffolds like 3,5-bis(pyridin-3-yl)-1,2,4-thiadiazole (2) is <lb/>inhibitor of aromatase and used for treatment of various types <lb/>of cancers [56, 57]. <lb/></body>

			123 <lb/>

			<page>226 <lb/></page>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<body>Fig. 1 Structures of letrozole (1) <lb/>and 3,5-bis(pyridine-3-yl)-1,2,4-<lb/>thiadiazole <lb/>(2) <lb/>Previously, we reported the synthesis of a library of <lb/>novel <lb/>2-(4-arylsubstituted-1H-1,2,3-triazol-1-yl)-N-{4-<lb/>[2-(thiazol-2-yl)benzo[d]thiazol-6-yl]phenyl}acetamide <lb/>derivatives and screened their anticancer activities against <lb/>MCF-7, A549, Colo-205, and A2780 cell lines with etopo-<lb/>side as standard drug. The anticancer target compounds <lb/>reported by us and the literature reveal hazardous sol-<lb/>vent usage, harsh reaction conditions, and longer reaction <lb/>sequences. To overcome the above drawbacks and inspired by <lb/>special features of both 1,2,4-triazole and 1,2,4-oxadiaxole, <lb/>we have to design and synthesize new amide functionality <lb/>bearing 1,2,4-thiadiazole-1,2,4-triazole derivatives (8a-j). <lb/>These derivatives were examined for their anticancer activi-<lb/>ties against four different human cancer cell lines like breast <lb/>cancer (MCF-7, MDA MB-231), lung cancer (A549), and <lb/>prostate cancer (DU-145). These derivatives may act as drug <lb/>lead molecules in cancer chemotherapy. <lb/>2 Experimental <lb/>2.1 General Conditions <lb/>All the solvents, salts, reagents, and fine chemicals were <lb/>purchased from Sigma-Aldrich and Alfa Aesar companies. <lb/>These chemical items were used without further purification. <lb/>1 H and 13 C NMR spectra were recorded with 400 MHz and <lb/>300 MHz frequency Gemini Varian-VXR-unity instruments. <lb/>Chemical shifts (δ) were noted in ppm toward downfield with <lb/>respect to tetramethylsilane as internal standard. ESI spectra <lb/>were recorded at 3.98 kV capillary voltages with micro-mass, <lb/>Quattro LC instrument using ESI + software. Melting points <lb/>were noted with the help of electrothermal melting point <lb/>apparatus. <lb/>2.2 Synthesis <lb/>2.2.1 5-(3,4,5-Trimethoxyphenyl)-3-p-Tolyl-1H-1,2,4-<lb/>Triazole <lb/>(5) <lb/>To a dried 250-mL round-bottom flask were added 4-<lb/>methylbenzonitrile (4) (4.7 mL, 0.039 mol), 3,4,5-trimethoxy <lb/>benzamidine (3) (14 g, 0.066 mol), Cs 2 CO 3 (43 g, <lb/>0.316 mol), CuBr (312 mg, 0.00217 mol, 5 mol%), and <lb/>DMSO (80 mL). The reaction mixture was stirred under <lb/>atmospheric air at 120 °C for 24 h. After cooling to atmo-<lb/>spheric temperature, the reaction mixture was extracted with <lb/>ethyl acetate solvent (3 × 15 <lb/>45 mL) and successively <lb/>washed with 5% aqueous NaHCO 3 (3 × 10 30 mL) and <lb/>brine (10 mL). The organic layer was dried on MgSO 4 and <lb/>concentrated under reduced pressure. The crude residue was <lb/>purified with silica gel through column chromatography by <lb/>using 2:8 ratio ethyl acetate/hexane solvent mixture to afford <lb/>pure yellow color compound 5 as 13.8 g with 64% yield. Mp: <lb/>166-168 °C. 1 HNMR (400 MHz, DMSO-d 6 ): δ 2.43 (s, 3H, <lb/>-CH 3 ), 3.72 (s, 3H, -OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 7.73 (d, <lb/>2H, J <lb/>8.2 Hz), 7.89 (s, 2H), 8.29 (d, 2H, J <lb/>8.2 Hz), <lb/>10.32 (brs, 1H, -NH); 13 C NMR (75 MHz, DMSO-d 6 ): δ <lb/>22.8, 56.2, 60.9, 107.3, 124.5, 126.9, 128.6, 133.3, 141.6, <lb/>141.9, 155.8, 162.4, 169.1; MS (ESI): m/z 326 [M + H] + . <lb/>2.2.2 5-(3,4,5-Trimethoxyphenyl)-3-(4-(3-(3,4,5-<lb/>Trimethoxyphenyl)-1,2,4-Thiadiazol-5-yl)Phenyl)-1H-<lb/>1,2,4-Triazole <lb/>(6) <lb/>A mixture of 5-(3,4,5-trimethoxyphenyl)-3-p-tolyl-1H-<lb/>1,2,4-triazole (5) (12 g, 0.037 mol), 3,4,5-trimethoxy benza-<lb/>midine (3) (15.5 g, 0.0738 mol), sulfur S (5.9 g, 0.185 mol), <lb/>potassium phosphate tribasic trihydrate (29.5 g, 0.111 mol), <lb/>and DMSO (100 mL) was discharged in 200 mL of dried <lb/>round-bottom flask under air. The reaction vessel was stirred <lb/>at 130 °C for 12 h. After cooling to 27 °C, the solvent was <lb/>removed under reduced pressure. The crude residue was puri-<lb/>fied on silica gel through column chromatography with 3:7 <lb/>ratio of ethyl acetate/hexane solvent mixture to afford the <lb/></body>

			123 <lb/>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<page>227 <lb/></page>

			<body>desired yellow color product 6 as 14.6 g with 71% yield. <lb/>Mp: 196-198 °C; 1 HNMR (400 MHz, DMSO-d 6 ): δ 3.72 (s, <lb/>3H, -OCH 3 ), 3.79 (s, 6H, 2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), <lb/>3.92 (s, 3H, -OCH 3 ), 7.78 (s, 2H), 7.89 (d, 2H, J 8.4 Hz), <lb/>8.10 (s, 2H), 8.49 (d, 2H, J 8.4 Hz), 10.34 (brs, 1H, -NH); <lb/>13 C NMR (75 MHz, DMSO-d 6 ): δ 56.3, 56.6, 60.8, 106.6, <lb/>108.7, 124.2, 124.6, 128.9, 130.1, 133.6, 136.5, 142.8, 144.1, <lb/>154.2, 155.1, 162.4, 168.9, 171.4, 184.2; MS (ESI): m/z 562 <lb/>[M + H] + . <lb/>2.2.3 (5-(3,4,5-Trimethoxyphenyl)-3-(4-(3-(3,4,5-<lb/>Trimethoxyphenyl)-1,2,4-Thiadiazol-5-yl)Phenyl)-1H-<lb/>1,2,4-Triazol-1-yl)(Phenyl)Methanone <lb/>(8a) <lb/>The compound 5-(3,4,5-trimethoxyphenyl)-3-(4-(3-(3,4,5-<lb/>trimethoxyphenyl)-1,2,4-thiadiazol-5-yl)phenyl)-1H-1,2,4-<lb/>triazole (6) (500 mg, 0.891 mol) was dissolved in 40 mL <lb/>of dry acetonitrile, followed by addition of benzoyl chlo-<lb/>ride (7a) (0.1 mL, 0.891 mmol) and Cs 2 CO 3 (580 mg, <lb/>1.78 mol). The reaction mixture allowed for stirring at room <lb/>temperature over a time period of 12 h. After completion of <lb/>reaction, the reaction mass was washed with 3 mL water and <lb/>diluted with dichloromethane (3 × 3 9 mL). It was dried <lb/>on anhydrous Na 2 SO 4 . The crude residue was purified with <lb/>silica gel through column chromatography by using 1:1 ratio <lb/>ethyl acetate/hexane solvent mixture and then afforded pure <lb/>yellow color compound 8a in 310.8 mg, 53% yield. Mp: <lb/>178-180 °C, 1 H NMR (300 MHz, DMSO-d 6 ): δ 3.72 (s, <lb/>3H, -OCH 3 ), 3.79 (s, 6H, 2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), <lb/>3.92 (s, 3H, -OCH 3 ), 7.58-7.62 (m, 1H), 7.67-7.73 (m, 2H), <lb/>7.79 (s, 2H), 7.93 (d, 2H, J <lb/>8.5 Hz), 8.15 (d, 2H, J <lb/>7.6 Hz), 8.48 (s, 2H), 8.66 (d, 2H, J 8.5 Hz); 13 C NMR <lb/>(75 MHz, DMSO-d 6 ): δ 57.6, 58.5, 61.4, 61.8, 106.7, 109.5, <lb/>116.4, 125.7, 129.3, 129.7, 132.2, 132.5, 134.3, 135.7, <lb/>136.3, 137.6, 142.4, 144.5, 153.4, 154.6, 155.4, 164.5, <lb/>168.7, 169.4, 176.7; MS (ESI): m/z 666 [M + H] + . <lb/>2.2.4 (3,4,5-Trimethoxyphenyl)(5-(3,4,5-<lb/>Trimethoxyphenyl)-3-(4-(3-(3,4,5-Trimethoxyphenyl)-<lb/>1,2,4-Thiadiazol-5-yl)Phenyl)-1H-1,2,4-Triazol-1-<lb/>yl)Methanone <lb/>(8b) <lb/>This compound 8b was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 3,4,5-trimethoxybenzoyl chloride (7b) <lb/>(206 mg, 0.891 mmol), Cs 2 CO 3 (580 mg, 1.78 mol), and <lb/>the crude residue was purified with silica gel through col-<lb/>umn chromatography by using 1:1 ratio ethyl acetate/hexane <lb/>solvent mixture and then afforded pure yellow color com-<lb/>pound 8b, 338.4 mg in 50% yield. Mp: 200-202 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.65 (s, 3H, -OCH 3 ), 3.72 (s, 3H, <lb/>-OCH 3 ), 3.80 (s, 6H, 2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.92 <lb/>(s, 3H, -OCH 3 ), 3.95 (s, 6H, 2-OCH 3 ), 7.68 (s, 2H), 7.79 (s, <lb/>2H), 7.92 (d, 2H, J 8.4 Hz), 8.47 (s, 2H), 8.67 (d, 2H, J <lb/>8.4 Hz); 13 C NMR (75 MHz, DMSO-d 6 ): δ 57.4, 57.8, 58.5, <lb/>61.4, 61.7, 62.4, 106.7, 107.8, 109.3, 116.5, 125.6, 131.5, <lb/>132.4, 133.7, 134.5, 137.2, 142.9, 144.7, 145.8, 153.6, 154.3, <lb/>155.8, 157.9, 162.5, 168.5, 169.4, 176.8; MS (ESI): m/z 756 <lb/>[M + H] + . <lb/>2.2.5 (3,5-Dimethoxyphenyl)(5-(3,4,5-Trimethoxyphenyl)-<lb/>3-(4-(3-(3,4,5-Trimethoxyphenyl)-1,2,4-Thiadiazol-5-<lb/>yl)Phenyl)-1H-1,2,4-Triazol-1-yl)Methanone <lb/>(8c) <lb/>This compound 8c was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 3,5-dimethoxybenzoyl chloride (7c) <lb/>(179 mg, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the <lb/>crude residue was purified with silica gel through column <lb/>chromatography by using 1:1 ratio ethyl acetate/hexane sol-<lb/>vent mixture and then afforded pure yellow color compound <lb/>8c, 320.6 mg in 50% yield. Mp: 190-192 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.67 (s, 3H, -OCH 3 ), 3.72 (s, 3H, <lb/>-OCH 3 ), 3.80 (s, 6H, 2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.92 <lb/>(s, 3H, -OCH 3 ), 7.24 (s, 1H), 7.34 (s, 2H), 7.79 (s, 2H), 7.93 <lb/>(d, 2H, J 8.5 Hz), 8.47 (s, 2H), 8.66 (d, 2H, J 8.5 Hz); <lb/>13 C NMR (75 MHz, DMSO-d 6 ): δ 56.7, 57.8, 58.5, 61.5, <lb/>62.4, 106.5, 108.2, 109.7, 116.4, 120.5, 125.5, 132.4, 133.6, <lb/>133.9, 134.6, 137.4, 142.3, 144.8, 153.2, 154.6, 155.8, 162.3, <lb/>166.8, 168.2, 169.6, 176.8; MS (ESI): m/z 726 [M + H] + . <lb/>2.2.6 (4-Methoxyphenyl)(5-(3,4,5-Trimethoxyphenyl)-3-(4-<lb/>(3-(3,4,5-Trimethoxyphenyl)-1,2,4-Thiadiazol-5-<lb/>yl)Phenyl)-1H-1,2,4-Triazol-1-yl)Methanone <lb/>(8d) <lb/>This compound 8d was prepared following the method <lb/>described for the preparation of the compound 8a, employ-<lb/>ing 6 (500 mg, 0.891 mol) with 4-methoxybenzoyl chloride <lb/>(7d) (0.12 mL, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and <lb/>the crude residue was purified with silica gel through col-<lb/>umn chromatography by using 1:1 ratio ethyl acetate/hexane <lb/>solvent mixture and then afforded afford pure yellow color <lb/>compound 8d, 312.8 mg in 51% yield. Mp: 195-197 °C, 1 H <lb/>NMR (300 MHz, DMSO-d 6 ): δ 3.72 (s, 3H, -OCH 3 ), 3.76 (s, <lb/>3H, -OCH 3 ), 3.80 (s, 6H, 2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), <lb/>3.92 (s, 3H, -OCH 3 ), 7.79 (s, 2H), 7.91-8.07 (m, 4H), 8.17 <lb/>(d, 2H, J 7.9 Hz), 8.47 (s, 2H), 8.67 (d, 2H, J 8.6 Hz); <lb/>13 C NMR (75 MHz, DMSO-d 6 ): δ 56.7, 57.6, 58.7, 61.4, <lb/>62.5, 106.5, 109.2, 114.7, 116.8, 125.4, 130.2, 131.4, 132.6, <lb/>133.8, 134.6, 137.4, 142.3, 144.6, 153.7, 154.5, 155.8, 164.2, <lb/>166.8, 168.4, 169.7, 176.7; MS (ESI): m/z 696 [M + H] + . <lb/></body>
				
			123 <lb/>

			<page>228 <lb/></page>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<body>2.2.7 (5-(3,4,5-Trimethoxyphenyl)-3-(4-(3-(3,4,5-<lb/>Trimethoxyphenyl)-1,2,4-Thiadiazol-5-yl)Phenyl)-1H-<lb/>1,2,4-Triazol-1-yl)(4-Nitrophenyl)Methanone <lb/>(8e) <lb/>This compound 8e was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 4-nitrobenzoyl chloride (7e) (165 mg, <lb/>0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude <lb/>residue was purified with silica gel through column chro-<lb/>matography by using 1:1 ratio ethyl acetate/hexane solvent <lb/>mixture and then afforded pure yellow color compound <lb/>8e, 385.4 mg in 61% yield. Mp: 230-232 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.72 (s, 3H, -OCH 3 ), 3.83 (s, 6H, <lb/>2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.93 (s, 3H, -OCH 3 ), 7.80 <lb/>(s, 2H), 7.94 (d, 2H, J 8.7 Hz), 8.30 (d, 2H, J 8.1 Hz), <lb/>8.40 (d, 2H, J <lb/>8.1 Hz), 8.49 (s, 2H), 8.68 (d, 2H, J <lb/>8.7 Hz); 13 C NMR (75 MHz, DMSO-d 6 ): δ 57.6, 58.7, 61.4, <lb/>62.7, 106.4, 109.7, 116.8, 125.3, 126.5, 131.2, 132.6, 133.5, <lb/>134.8, 137.6, 141.3, 142.6, 44.5, 153.4, 154.6, 154.9, 155.6, <lb/>164.5, 168.4, 169.7, 176.8; MS (ESI): m/z 711 [M + H] + . <lb/>2.2.8 (5-(3,4,5-Trimethoxyphenyl)-3-(4-(3-(3,4,5-<lb/>Trimethoxyphenyl)-1,2,4-Thiadiazol-5-yl)Phenyl)-1H-<lb/>1,2,4-Triazol-1-yl)(3,5-Dinitrophenyl)Methanone <lb/>(8f) <lb/>This compound 8f was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 3,5-dinitrobenzoyl chloride (7f) (205 mg, <lb/>0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude <lb/>residue was purified with silica gel through column chro-<lb/>matography by using 1:1 ratio ethyl acetate/hexane solvent <lb/>mixture and then afforded pure yellow color compound <lb/>8f, 410.5 mg in 61% yield. Mp: 254-256 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.73 (s, 3H, -OCH 3 ), 3.84 (s, 6H, <lb/>2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.95 (s, 3H, -OCH 3 ), 7.80 <lb/>(s, 2H), 7.94 (d, 2H, J 8.8 Hz), 8.52 (s, 2H), 8.68 (d, 2H, <lb/>J 8.8 Hz), 8.92 (s, 2H), 9.14 (s, 1H); 13 C NMR (75 MHz, <lb/>DMSO-d 6 ): δ 57.6, 58.4, 61.5, 62.7, 106.4, 109.7, 116.6, <lb/>125.4, 126.7, 128.5, 132.4, 133.6, 134.5, 135.7, 137.4, 142.3, <lb/>144.5, 148.6, 153.4, 154.6, 155.7, 157.6, 168.4, 169.7, 176.8; <lb/>MS (ESI): m/z 756 [M + H] + . <lb/>2.2.9 (4-Chlorophenyl)(5-(3,4,5-Trimethoxyphenyl)-3-(4-(3-<lb/>(3,4,5-Trimethoxyphenyl)-1,2,4-Thiadiazol-5-<lb/>yl)Phenyl)-1H-1,2,4-Triazol-1-yl)Methanone <lb/>(8g) <lb/>This compound 8g was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 4-chlorobenzoyl chloride (7 g) (0.11 mL, <lb/>0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude <lb/>residue was purified with silica gel through column chro-<lb/>matography by using 1:1 ratio ethyl acetate/hexane solvent <lb/>mixture and then afforded pure yellow color compound <lb/>8g, 348.7 mg in 56% yield. Mp: 233-235 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.73 (s, 3H, -OCH 3 ), 3.82 (s, 6H, <lb/>2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.93 (s, 3H, -OCH 3 ), 7.73 <lb/>(d, 2H, J 8.02 Hz), 7.80 (s, 2H), 7.94 (d, 2H, J 8.7 Hz), <lb/>8.19 (d, 2H, J 8.02 Hz), 8.50 (s, 2H), 8.68 (d, 2H, J <lb/>8.7 Hz); 13 C NMR (75 MHz, DMSO-d 6 ): δ 57.6, 58.7, 61.5, <lb/>62.8, 106.5, 109.8, 116.5, 125.4, 130.5, 132.5, 133.2, 134.7, <lb/>135.2, 135.7, 137.5, 142.3, 142.6, 144.5, 153.4, 154.6, 155.8, <lb/>164.3, 168.3, 169.7, 176.8; MS (ESI): m/z 700 [M + H] + . <lb/>2.2.10 (4-Bromophenyl)(5-(3,4,5-Trimethoxyphenyl)-3-(4-<lb/>(3-(3,4,5-Trimethoxyphenyl)-1,2,4-Thiadiazol-5-<lb/>yl)Phenyl)-1H-1,2,4-Triazol-1-yl)Methanone <lb/>(8h) <lb/>This compound 8h was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 4-bromobenzoyl chloride (7h) (196 mg, <lb/>0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude <lb/>residue was purified with silica gel through column chro-<lb/>matography by using 1:1 ratio ethyl acetate/hexane solvent <lb/>mixture and then afforded pure yellow color compound <lb/>8h, 336.2 mg in 51% yield. Mp: 241-243 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.73 (s, 3H, -OCH 3 ), 3.82 (s, 6H, 2-<lb/>OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.93 (s, 3H, -OCH 3 ), 7.78 (d, <lb/>2H, J 8.00 Hz), 7.80 (s, 2H), 7.94 (d, 2H, J 8.6 Hz), 8.15 <lb/>(d, 2H, J 8.00 Hz), 8.51 (s, 2H), 8.68 (d, 2H, J 8.6 Hz); <lb/>13 C NMR (100 MHz, DMSO-d 6 ): δ 57.5, 58.7, 61.4, 62.7, <lb/>106.8, 109.8, 116.4, 125.6, 126.3, 130.2, 132.4, 133.2, 134.5, <lb/>134.7, 135.6, 137.6, 142.4, 144.5, 153.2, 154.6, 155.8, 164.5, <lb/>168.4, 169.8, 177.1; MS (ESI): m/z 746 [M + H] + . <lb/>2.2.11 4-[(5-(3,4,5-Trimethoxyphenyl)-3-4-[3-(3,4,5-<lb/>Trimethoxyphenyl)-1,2,4-Thiadiazol-5-yl]Phenyl-1H-<lb/>1,2,4-Triazol-1-yl)Carbonyl]Benzonitrile <lb/>(8i) <lb/>This compound 8i was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 4-cyanobenzoyl chloride (7i) (148 mg, <lb/>0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude <lb/>residue was purified with silica gel through column chro-<lb/>matography by using 1:1 ratio ethyl acetate/hexane solvent <lb/>mixture and then afforded pure yellow color compound <lb/>8i, 156.8 mg in 26% yield. Mp: 247-249 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 3.73 (s, 3H, -OCH 3 ), 3.82 (s, 6H, <lb/>2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.93 (s, 3H, -OCH 3 ), 7.81 <lb/>(s, 2H), 7.94 (d, 2H, J 8.6 Hz), 8.21 (d, 2H, J 8.04 Hz), <lb/>8.39 (d, 2H, J 8.04 Hz), 8.53 (s, 2H), 8.68 (d, 2H, J <lb/>8.6 Hz); 13 C NMR (75 MHz, DMSO-d 6 ): δ 57.4, 58.6, 61.6, <lb/></body>

			123 <lb/>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<page>229 <lb/></page>

			<body>62.7, 106.4, 109.7, 114.6, 116.7, 119.4, 125.4, 131.2, 132.5, <lb/>133.6, 134.2, 135.8, 137.3, 138.6, 142.5, 144.7, 153.4, 154.7, <lb/>155.6, 164.2, 168.6, 169.7, 177.3; MS (ESI): m/z 691 [M + <lb/>H] + . <lb/>2.2.12 (5-(3,4,5-Trimethoxyphenyl)-3-(4-(3-(3,4,5-<lb/>Trimethoxyphenyl)-1,2,4-Thiadiazol-5-yl)Phenyl)-<lb/>1H-1,2,4-Triazol-1-yl)(p-Tolyl)Methanone <lb/>(8j) <lb/>This compound 8j was synthesized by the same method <lb/>involved in the synthesis of 8a, employing 6 (500 mg, <lb/>0.891 mol) with 4-methylbenzoyl chloride (7j) (0.8 mL, <lb/>0.891 mmol), Cs 2 CO 3 (580 mg, 1.78 mmol), and the crude <lb/>residue was purified with silica gel through column chro-<lb/>matography by using 1:1 ratio ethyl acetate/hexane solvent <lb/>mixture and then afforded pure yellow color compound <lb/>8j, 362.4 mg in 60% yield. Mp: 186-188 °C, 1 H NMR <lb/>(300 MHz, DMSO-d 6 ): δ 2.45 (s, 3H, -CH 3 ), 3.73 (s, 3H, <lb/>-OCH 3 ), 3.81 (s, 6H, 2-OCH 3 ), 3.89 (s, 6H, 2-OCH 3 ), 3.92 <lb/>(s, 3H, -OCH 3 ), 7.68 (d, 2H, J 7.9 Hz), 7.81 (s, 2H), 7.94 <lb/>(d, 2H, J 8.6 Hz), 8.18 (d, 2H, J 7.9 Hz), 8.49 (s, 2H), <lb/>8.68 (d, 2H, J 8.6 Hz); 13 C NMR (75 MHz, DMSO-d 6 ): δ <lb/>24.8, 57.6, 58.3, 61.4, 62.6, 106.7, 109.5, 116.3, 125.7, 129.4, <lb/>130.2, 132.5, 133.6, 134.4, 135.3, 137.5, 142.4, 144.7, 146.6, <lb/>153.2, 154.6, 155.8, 164.5, 168.4, 169.7, 176.9; MS (ESI): <lb/>m/z 680 [M + H] + . <lb/>2.3 MTT Assay <lb/>Individual wells microtiter plate from a 96-well tissue culture <lb/>was inoculated with 100 μL of complete medium contain-<lb/>ing 1 × 10 4 cells. These microtiter plates were incubated at a <lb/>temperature of 37 °C in 5% CO 2 -humidified incubator over a <lb/>time period of 18 h prior to the experiment. After the removal <lb/>of medium, a fresh medium of 100 μL containing both the <lb/>test compounds and standard drug and etoposide at a variable <lb/>concentrations of 0.5, 1, 2, and 4 μM was added to each well <lb/>and incubated over 24-h time period at 37 °C temperature. <lb/>Now, this medium was removed and replaced by 10 μL MTT <lb/>assay dye. Again, the plates were allowed for incubation at a <lb/>temperature of 37 °C over 2-h time period. The obtained for-<lb/>mazan crystals were dissolved in 100 μL extraction buffer. <lb/>The OD value was read with multimode Varioskan Instru-<lb/>ment, Themo Scientific microplate reader at 570 nm. The <lb/>% of DMSO-d 6 in the medium should not exceed 0.25% at <lb/>any time. Each of the data of the IC 50 values were repre-<lb/>sented as mean of ± SD values that means each experiment <lb/>was performed three times. <lb/>3 Results and Discussion <lb/>3.1 Chemistry <lb/>The synthesis of 1,2,4-thiadiazole-1,2,4-triazole derivatives <lb/>bearing amide functionality (8a-j) is shown in Scheme 1. <lb/>Starting material 3,4,5-trimethoxybenzamidine (3) under-<lb/>goes cyclization reaction with 4-methylbenzonitrile (4) in the <lb/>presence of CuBr catalyst, Cs 2 CO 3 base in DMSO solvent at <lb/>120 °C temperature over 24 h to afford triazole intermediate <lb/>5. The ESI-MS peak at m/z 326 [M + H] + confirmed the <lb/>structure of compound 5. The triazole compound 5 reacted <lb/>with 3,4,5-trimethoxybenzamidine (3) in the presence of <lb/>potassium phosphate tribasic trihydrate (K 3 PO 4 •3H 2 O) base, <lb/>and sulfur in DMSO solvent was heated at 130 °C for <lb/>12 h to afford pure 1,2,4-thiadiazole intermediate 6. The <lb/>ESI-MS peak at m/z 562 [M + H] + confirmed the structure <lb/>of compound 6. Then, this intermediate 5 was coupled with <lb/>substituted aromatic acid chlorides (7a-j) in the presence <lb/>of Cs 2 CO 3 base in anhydrous acetonitrile solvent at room <lb/>temperature for 12 h to afford the 1,2,4-thiadiazole-1,2,4-<lb/>triazole derivatives 8a-j. The ESI-MS peak at m/z 666 [M + <lb/>H] + confirmed the structure of compound 8a. <lb/>The new library of 1,2,4-thiadiazole-1,2,4-triazole deriva-<lb/>tives having amide functionality (8a-j). <lb/>3.2 Biological Evaluation <lb/>3.2.1 In Vitro Cytotoxicity <lb/>The new library of 1,2,4-thiadiazole-1,2,4-triazole deriva-<lb/>tives having amide functionality (8a-j), was examined for <lb/>their anticancer activity toward a pane of four different <lb/>human cancer cell lines such as breast cancer (MCF-7, <lb/>MDA MB-231), lung cancer (A549), and prostate cancer <lb/>(DU-145) by MTT assay and compared with the standard <lb/>reference etoposide. The obtained results were presented <lb/>as IC 50 (μM) values in Table 1. The results indicated <lb/>that most of the synthesized compounds exhibited moder-<lb/>ate to excellent anticancer activity aligned with four cell <lb/>lines. Among the library of examined compounds, com-<lb/>pounds 8b, 8c, 8d, 8e, 8g, and 8i displayed more potent <lb/>activity with IC 50 values ranging from 0.10 ± 0.084 to <lb/>11.5 ± 6.49 μM and standard showed IC 50 value range as <lb/>1.91 ± 0.84 μM to 3.08 ± 0.135 μM. Further, all these com-<lb/>pounds were investigated for structure-activity relationship <lb/>(SARs) studies. Compound 8b with electron-donating group <lb/>(3,4,5-trimethoxy) showed highest anticancer activity toward <lb/>MCF-7, A549, DU-145, and MDA MB-231 with IC 50 val-<lb/>ues of 0.10 ± 0.084 μM, 0.17 ± 0.032 μM, 0.83 ± 0.091 μM, <lb/>and 0.28 ± 0.017 μM, respectively, where slight decrease in <lb/>activity was observed for 8c and 8d with IC 50 values of <lb/>MCF-7 1.12 ± 0.64 μM; A549 1.79 ± 0.59 μM; DU145 <lb/></body>

			123 <lb/>

			<page>230 <lb/></page>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<body>Scheme 1 Synthesis of amide <lb/>functionality bearing <lb/>1,2,4-thiadiazole-1,2,4-triazole <lb/>derivatives <lb/>NH 2 <lb/>NH <lb/>MeO <lb/>MeO <lb/>MeO <lb/>MeO <lb/>MeO <lb/>MeO <lb/>N <lb/>H <lb/>N <lb/>N <lb/>NC <lb/>H 2 N <lb/>HN <lb/>OMe <lb/>OMe <lb/>OMe <lb/>K 3 PO 4 , S, <lb/>DMSO, 130 o C, 12h <lb/>OMe <lb/>MeO <lb/>MeO <lb/>HN N <lb/>N <lb/>S <lb/>N <lb/>N <lb/>MeO <lb/>OMe <lb/>OMe <lb/>Cl <lb/>O <lb/>R <lb/>MeCN, Cs 2 CO 3 <lb/>rt, 12h <lb/>MeO <lb/>MeO <lb/>MeO <lb/>N <lb/>N <lb/>N <lb/>S <lb/>N <lb/>N <lb/>MeO <lb/>OMe <lb/>OMe <lb/>O <lb/>R <lb/>3 <lb/>4 <lb/>5 <lb/>3 <lb/>6 <lb/>7a-j <lb/>8a-j <lb/>7a; R = H <lb/>7b; R = 3,4,5-trimethoxy <lb/>7c; R = 3,5-dimethoxy <lb/>7d; R = 4-methoxy <lb/>7e; R = 4-nitro <lb/>7f; R = 3,5-dinitro <lb/>7g; R = 4-chloro <lb/>7h; R = 4-bromo <lb/>7i; R = 4-cyano <lb/>7j; R = 4-methyl <lb/>8a; R = H <lb/>8b; R = 3,4,5-trimethoxy <lb/>8c; R = 3,5-dimethoxy <lb/>8d; R = 4-methoxy <lb/>8e; R = 4-nitro <lb/>8f; R = 3,5-dinitro <lb/>8g; R = 4-chloro <lb/>8h; R = 4-bromo <lb/>8i; R = 4-cyano <lb/>8j; R = 4-methyl <lb/>DMSO, 120 o C, 24h <lb/>CuBr, Cs 2 CO 3 <lb/>Table 1 In vitro cytotoxicity of <lb/>newly target compounds 8a-j <lb/>with IC 50 in μM <lb/>Compound <lb/>MCF-7 <lb/>A549 <lb/>DU-145 <lb/>MDA MB-231 <lb/>8a <lb/>3.57 ± 2.81 <lb/>2.98 ± 1.76 <lb/>ND <lb/>4.11 ± 2.30 <lb/>8b <lb/>0.10 ± 0.084 <lb/>0.17 ± 0.032 <lb/>0.83 ± 0.091 <lb/>0.28 ± 0.017 <lb/>8c <lb/>1.12 ± 0.64 <lb/>1.79 ± 0.59 <lb/>1.98 ± 0.22 <lb/>2.33 ± 1.52 <lb/>8d <lb/>1.44 ± 0.17 <lb/>2.10 ± 1.44 <lb/>2.76 ± 1.88 <lb/>2.35 ± 1.51 <lb/>8e <lb/>0.23 ± 0.014 <lb/>1.64 ± 0.53 <lb/>0.19 ± 0.011 <lb/>1.55 ± 0.63 <lb/>8f <lb/>5.66 ± 2.38 <lb/>ND <lb/>7.23 ± 4.52 <lb/>ND <lb/>8g <lb/>1.02 ± 0.65 <lb/>1.69 ± 0.13 <lb/>2.13 ± 1.98 <lb/>2.15 ± 1.08 <lb/>8h <lb/>7.28 ± 3.67 <lb/>ND <lb/>8.22 ± 4.33 <lb/>10.7 ± 5.26 <lb/>8i <lb/>1.27 ± 0.92 <lb/>1.90 ± 0.46 <lb/>0.60 ± 0.014 <lb/>1.59 ± 0.37 <lb/>8j <lb/>5.94 ± 3.26 <lb/>11.5 ± 6.49 <lb/>9.37 ± 6.21 <lb/>ND <lb/>Etoposide <lb/>2.11 ± 0.024 <lb/>3.08 ± 0.135 <lb/>1.97 ± 0.45 <lb/>1.91 ± 0.84 <lb/>ND Not determined <lb/>MCF-7: human breast cancer cell line. A549: human lung cancer cell line. DU-145: human prostate cancer <lb/>cell line. MDA MB-231: human breast cancer cell line <lb/>1.98 ± 0.22 μM, MDA MB-231 2.33 ± 1.52 μM, and <lb/>MCF-7 1.44 ± 0.17 μM; A549 2.10 ± 1.44 μM; DU145 <lb/>2.76 ± 1.88 μM, MDA MB-231 2.35 ± 1.51 μM, when <lb/>compared with 8b compound. The replacement of 4-methoxy <lb/>group with 4-nitro (8e) showed improved anticancer activity <lb/>against four cell lines (MCF-7 0.23 ± 0.014 μM; A549 <lb/>1.64 ± 0.53 μM; DU145 <lb/>0.19 ± 0.011 μM, MDA MB-<lb/>231 <lb/>1.55 ± 0.63 μM) compared with 8d. Replacement <lb/>of 4-nitro substituent with 4-chloro and then the compound <lb/>8g showed acceptable activity (MCF-7 1.02 ± 0.65 μM; <lb/>A549 <lb/>1.69 ± 0.13 μM; DU145 <lb/>2.13 ± 1.98 μM, <lb/>MDA MB-231 2.15 ± 1.08 μM). When 3,5-dinitro group <lb/>was introduced, 4-bromo substituents on the phenyl ring <lb/>resulted compounds, namely 8f and 8h, were displayed <lb/>very poor activity on all cell lines. Interestingly, compound <lb/>8i with 4-cyano electron-withdrawing group showed bet-<lb/>ter anticancer activity (MCF-7 1.27 ± 0.92 μM; A549 <lb/>1.90 ± 0.46 μM; DU145 <lb/>0.60 ± 0.014 μM, MDA MB-<lb/>231 1.59 ± 0.37 μM) than 8g. Compound 8j with weak <lb/>electron-donating group on the phenyl ring demonstrated <lb/>moderate activity. <lb/>From the structure-activity relationship studies, it can <lb/>be concluded that the presence of three electron-donating <lb/>-OCH 3 group at 3,4,5 positions on phenyl ring displayed <lb/></body>

			123 <lb/>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<page>231 <lb/></page>

			<body>excellent potent anticancer activities against four specified <lb/>cancer cell lines. The decrease in anticancer activity would <lb/>be observed with two -OCH 3 groups at 3,5 positions and <lb/>one -OCH 3 group at 4th position. The presence of strong-<lb/>withdrawing group -NO 2 at 3, 5 positions on phenyl ring <lb/>displayed very less anticancer activity against specified can-<lb/>cer cell lines, when compared to one -NO 2 group at 4th <lb/>position. In this series, cytotoxicity effect decreases from <lb/>the electron-donating group to electron-withdrawing group <lb/>derivatives. <lb/>4 Conclusion <lb/>The new library of 1,2,4-thiadiazole-1,2,4-triazole deriva-<lb/>tives having amide functionality (8a-j) was designed, syn-<lb/>thesized, and examined for their anticancer activities against <lb/>four different human cancer cell lines including breast cancer <lb/>(MCF-7, MDA MB-231), lung cancer (A549), and prostate <lb/>cancer (DU-145) by making use of MTT assay. Here, Etopo-<lb/>side acts as standard drug, and the obtained results were <lb/>presented as IC 50 (μM) values. The results indicated that <lb/>most of the synthesized compounds exhibited moderate to <lb/>excellent anticancer activity aligned with four cell lines. <lb/>Among them, compounds 8b, 8c, 8d, 8e, 8g, and 8i dis-<lb/>played more potent activity with IC 50 values ranging from <lb/>0.10 ± 0.084 to 11.5 ± 6.49 μM and standard showed IC 50 <lb/>value ranges from 1.91 ± 0.84 μM to 3.08± 0.135 μM. <lb/>These derivatives may act as drug lead molecules in cancer <lb/>chemotherapy. <lb/></body>

			<listBibl>References <lb/>1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D.: <lb/>Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011) <lb/>2. Park, S.K.; Cho, L.Y.; Yang, J.J.; Park, B.; Chang, S.H.; Lee, K.S.; <lb/>Kim, H.; Yoo, K.Y.; Lee, C.T.: Lung cancer risk and cigarette <lb/>smoking, lung tuberculosis according to histologic type and gender <lb/>in a population based case-control study. Lung Cancer 68, 20-26 <lb/>(2010) <lb/>3. Meffert, M.K.; Chang, J.M.; Wiltgen, B.J.; Fanselow, M.S.; Bal-<lb/>timore, D.: NF-kappa B functions in synaptic signalling and <lb/>behaviour. Nat. Neurosci. 6, 1072-1078 (2003) <lb/>4. Clemens, M.R.: Free radicals in chemical carcinogenesis. Klin. <lb/>Wochenschr. 69, 1123-1134 (1991) <lb/>5. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F.: Cancer-related <lb/>inflammation. Nature 454, 436-444 (2008) <lb/>6. Clayton, P.E.; Banerjee, I.; Murray, P.G.; Renehan, A.G.: Growth <lb/>hormone, the insulin-like growth factor axis, insulin and cancer <lb/>risk. Nat. Rev. Endocrinol. 7, 11-24 (2011) <lb/>7. Porta, C.; Riboldi, E.; Sica, A.: Mechanisms linking pathogens-<lb/>associated inflammation and cancer. Cancer Lett. 305, 250-262 <lb/>(2011) <lb/>8. Khan, F.A.; Akhtar, S.S.; Sheikh, M.K.: Cancer treatment-objec-<lb/>tives and quality of life issues. Malays. J. Med. Sci. 12, 3-5 (2005) <lb/>9. Menta, E.; Palumbo, M.: Novel antineoplastic agents. Exp. Opin. <lb/>Ther. Patents 7, 1401-1426 (1997) <lb/>10. Nussbaumer, S.; Bonnabry, P.; Veuthey, J.-L.; Fleury-Souverain, <lb/>S.: Analysis of anticancer drugs: a review. Talanta 85, 2265-2289 <lb/>(2011) <lb/>11. Rebucci, M.; Michiels, C.: Molecular aspects of cancer cell <lb/>resistance to chemotherapy. Biochem. Pharmacol. 85, 1219-1226 <lb/>(2013) <lb/>12. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G.: <lb/>Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, <lb/>714-726 (2013) <lb/>13. Rosa, R.; Monteleone, F.; Zambrano, N.; Bianco, R.: In vitro and <lb/>in vivo models for analysis of resistance to anticancer molecular <lb/>molecular therapies. Curr. Med. Chem. 21, 1595-1606 (2014) <lb/>14. Reddy, N.B.; Burra, V.R.; Ravindranath, L.K.; Sreenivasulu, R.; <lb/>Kumar, V.N.: Synthesis and biological evaluation of benzoxazole <lb/>fused combretastatin derivatives as anticancer agents. Monatsh. <lb/>Chem. 147, 593-598 (2016) <lb/>15. Reddy, N.B.; Burra, V.R.; Ravindranath, L.K.; Kumar, V.N.; <lb/>Sreenivasulu, R.; Sadanandam, P.: Synthesis and biological eval-<lb/>uation of benzimidazole fused ellipticine derivatives as anticancer <lb/>agents. Monatsh. Chem. 147, 599-604 (2016) <lb/>16. Hatti, I.; Sreenivasulu, R.; Jadav, S.S.; Jayaprakash, V.; Kumar, <lb/>C.G.; Raju, R.R.: Synthesis, cytotoxic activity and docking studies <lb/>of new 4-aza podophyllotoxin derivatives. Med. Chem. Res. 24, <lb/>3305-3313 (2015) <lb/>17. Sreenivasulu, R.; Reddy, K.T.; Sujitha, P.; Ganesh, C.; Raju, R.R.: <lb/>Synthesis, antiproliferative and apoptosis induction potential activ-<lb/>ities of novel bis(indolyl)hydrazide-hydrazone derivatives. Bioorg. <lb/>Med. Chem. 27, 1043-1055 (2019) <lb/>18. Agarwal, M.; Singh, V.; Sharma, S.C.; Sharma, P.; Ansari, MdY; <lb/>Jadav, S.S.; Yasmin, S.; Sreenivasulu, R.; Hassan, MdH: Design <lb/>and synthesis of new 2,5-disubstituted 1,3,4-oxadiazole analogues <lb/>as anticancer agents. Med. Chem. Res. 25, 2289-2303 (2016) <lb/>19. Spandana, Z.; Sreenivasulu, R.; Rekha, T.M.; Rao, M.V.B.: Novel <lb/>1,3,4-oxadiazole fused thiadiazole derivatives: synthesis and study <lb/>of anticancer activities. Lett. Drug Des. Discov. 16, 656-662 (2019) <lb/>20. Madhavi, S.; Sreenivasulu, R.; Raju, R.R.: Synthesis and biologi-<lb/>cal evaluation of oxadiazole incorporated ellipticine derivatives as <lb/>anticancer agents. Monatsh. Chem. 148, 933-938 (2017) <lb/>21. Sreenivasulu, R.; Durgesh, R.; Jadav, S.S.; Sujitha, P.; Kumar, C.G.; <lb/>Raju, R.R.: Synthesis, anticancer evaluation and molecular docking <lb/>studies of bis(indolyl)triazinones, nortopsentin analogues. Chem. <lb/>Pap. 72, 1369-1378 (2018) <lb/>22. Subramanyam, M.; Sreenivasulu, R.; Rambabu, G.; Rao, M.V.B.; <lb/>Rao, K.P.: Synthesis, biological evaluation and docking studies <lb/>of 1,3,4-oxadiazole fused benzothiazole derivatives for anticancer <lb/>drugs. Lett. Drug Des. Discov. 15, 1299-1307 (2018) <lb/>23. Ahsan, M.J.; Choudhary, K.; Jadav, S.S.; Yasmin, S.; Ansari, M.Y.; <lb/>Sreenivasulu, R.: Synthesis, antiproliferative activity and molecu-<lb/>lar docking studies of curcumin analogues bearing pyrazole ring. <lb/>Med. Chem. Res. 24, 4166-4180 (2015) <lb/>24. Madhavi, S.; Sreenivasulu, R.; Jyotsna, Y.; Raju, R.R.: Synthesis of <lb/>chalcone incorporated quinazoline derivatives as anticancer agents. <lb/>Saudi Pharm. J. 25, 275-279 (2017) <lb/>25. Hatti, I.; Sreenivasulu, R.; Jadav, S.S.; Ahsan, M.J.; Raju, R.R.: <lb/>Synthesis and biological evaluation of 1,3,4-oxadiazole linked <lb/>bis indole derivatives as anticancer agents. Monatsh. Chem. 146, <lb/>1699-1705 (2015) <lb/>26. Durgesh, R.; Sreenivasulu, R.; Pinapati, S.R.; Raju, R.R.: Synthe-<lb/>sis and anticancer evaluation of indazole-aryl hydrazide-hydrazone <lb/>derivatives. J. Ind. Chem. Soc. 95, 433-438 (2018) <lb/>27. Spandana, Z.; Sreenivasulu, R.; Rao, M.V.B.: Design, synthesis and <lb/>anticancer evaluation of carbazole fused aminopyrimidine deriva-<lb/>tives. Lett. Org. Chem. 16, 662-667 (2019) <lb/></listBibl>

			123 <lb/>

			<page>232 <lb/></page>

			<note place="headnote">Arabian Journal for Science and Engineering (2021) 46:225-232 <lb/></note>

			<listBibl>28. Madhavi, S.; Sreenivasulu, R.; Ansari, MdY; Ahsan, M.J.; Raju, <lb/>R.R.: Synthesis, biological evaluation and molecular docking stud-<lb/>ies of pyridine incorporated chalcone derivatives as anticancer <lb/>agents. Lett. Org. Chem. 13, 682-692 (2016) <lb/>29. Sreenivasulu, R.; Sujitha, P.; Jadav, S.S.; Ahsan, M.J.; Kumar, C.G.; <lb/>Raju, R.R.: Synthesis, antitumor evaluation and molecular dock-<lb/>ing studies of indole-indazolyl hydrazide-hydrazone derivatives. <lb/>Monatsh. Chem. 148, 305-314 (2017) <lb/>30. Reddy, K.T.; Sreenivasulu, R.; Raju, R.R.: Synthesis and biological <lb/>evaluation of 1,2,4-oxadiazole linked imidazopyrazine derivatives <lb/>as anticancer agents. J. Ind. Chem. Soc. 96, 1085-1090 (2019) <lb/>31. Murthy, I.S.; Sreenivasulu, R.; Alluraiah, G.; Raju, R.R.: Design, <lb/>synthesis and anticancer evaluation of 1,2,3-triazole linked 1,2-<lb/>isoxazole-imidazo[4,5-b]pyridine derivatives. Russ. J. Gen. Chem. <lb/>89, 1718-1723 (2019) <lb/>32. Kala, P.; Sharif, S.K.; Krishna, C.H.M.; Ramachandran, D.: Design, <lb/>synthesis and anticancer evaluation of 1,2,4-oxadiazole function-<lb/>alized quinolone derivatives. Med. Chem. Res. (2019). https://doi. <lb/>org/10.1007/s00044-019-02467-6 <lb/>33. Asami, T.; Min, Y.K.; Nagata, N.; Amagishi, K.Y.; Takatsuto, S.; <lb/>Fujioka, S.; Murofushi, N.; Yamaguchi, I.; Yoshida, S.: Characteri-<lb/>zation of brassinazole, a triazole-type brassinosteroid biosynthesis <lb/>inhibitor. Plant Physiol. 123, 93-100 (2000) <lb/>34. Kaur, P.; Chawla, A.: Hepatoprotective activity of Inula cappa DC. <lb/>Aqueous extract against carbon tetrachloride induced hepatotoxi-<lb/>city in Wistar rats. Int. Res. J. Pharm. 8, 14-19 (2017) <lb/>35. Kapron, B.; Luszczki, J.J.; Plaziska, A.; Siwek, A.; Karcz, T.; Gry-<lb/>bos, A.; Bowak, G.; Makuch-Kocka, A.; Walczak, K.; Langner, E.; <lb/>Szalast, K.; Marciniak, S.; Paczkowska, M.; Cielecka, J.; Ciesla, <lb/>L.M.; Plech, T.: Development of the 1,2,4-triazole-based anti-<lb/>convulsant drug candidates acting on the voltage-gated sodium <lb/>channels. Insights from in vivo, in vitro, and in silico studies. Eur. <lb/>J. Pharm. Sci. 129, 42-57 (2019) <lb/>36. Holla, B.S.; Poojary, K.N.; Rao, B.S.; Shivananda, M.: New bis-<lb/>aminomercapto triazoles and bis-triazolothiadiazoles as possible <lb/>anticancer agents. Eur. J. Med. Chem. 37, 511-517 (2002) <lb/>37. Eswaran, S.; Adhikari, A.V.; Shetty, N.S.: Synthesis and antimicro-<lb/>bial activities of novel quinoline derivatives carrying 1,2,4-triazole <lb/>moiety. Eur. J. Med. Chem. 44, 4637-4647 (2009) <lb/>38. Zhang, S.; Xu, Z.; Gao, C.; Ren, Q.C.; Chang, L.; Lv, Z.S.; Feng, <lb/>L.S.: Triazole derivatives and their anti-tubercular activity. Eur. J. <lb/>Med. Chem. 138, 501-513 (2017) <lb/>39. Jin, R.Y.; Zeng, C.Y.; Liang, X.H.; Sun, X.H.; Liu, Y.F.; Wang, <lb/>Y.Y.; Zhou, S.: Design, synthesis, biological activities and DFT <lb/>calculation of novel 1,2,4-triazole Schiff base derivatives. Bioorg. <lb/>Chem. 80, 253-260 (2018) <lb/>40. Wittine, K.; Babic, M.S.; Makuc, D.; Plavec, J.; Pavelic, S.; Sedic, <lb/>M.; Pavelic, K.; Leyssen, P.; Neyts, J.; Balzarini, J.; Mintas, M.: <lb/>Novel 1,2,4-triazole and imidazole derivatives of l-ascorbic and <lb/>imino-ascorbic acid: synthesis, anti-HCV and antitumor activity <lb/>evaluations. Bioorg. Med. Chem. 20, 3675-3685 (2012) <lb/>41. Mathew, V.; Keshavayya, J.; Vaidya, V.P.; Giles, D.: Studies on <lb/>synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-<lb/>triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues. Eur. <lb/>J. Med. Chem. 42, 823-840 (2007) <lb/>42. El Shehry, M.F.; Abu-Hashem, A.A.; El-Telbani, E.M.: Synthesis <lb/>of 3-((2,4-dichlorophenoxy)methyl)-1,2,4-triazolo(thiadiazoles <lb/>and thiadiazines) as anti-inflammatory and molluscicidal agents. <lb/>Eur. J. Med. Chem. 45, 1906-1911 (2010) <lb/>43. Zhang, Q.; Peng, Y.; Wang, X.I.; Keenan, S.M.; Arora, S.; <lb/>Welsh, W.J.: Highly potent triazole-based tubulin polymerization <lb/>inhibitors. J. Med. Chem. 50, 749-754 (2007) <lb/>44. Maiti, A.; Reddy, P.V.N.; Sturdy, M.; Marler, L.; Pegan, S.D.; Mese-<lb/>car, A.D.; Pezzuto, J.M.; Cushman, M.: Synthesis of casimiroin and <lb/>optimization of its quinone reductase 2 and aromatase inhibitory <lb/>activities. J. Med. Chem. 52, 1873-1884 (2009) <lb/>45. Stresser, D.M.; Turner, S.D.; McNamara, J.; Stocker, P.; Miller, <lb/>V.P.; Crespi, C.L.; Patten, C.J.: A high-throughput screen to identify <lb/>inhibitors of aromatase (CYP19). Anal. Biochem. 284, 427-430 <lb/>(2000) <lb/>46. Kumar, D.; Kumar, N.-M.; Chang, K.-H.; Shah, K.: Synthesis and <lb/>anticancer activity of 5-(3-indolyl)-1,3,4-thiadiazoles. Eur. J. Med. <lb/>Chem. 45, 4664-4668 (2010) <lb/>47. Unangst, P.C.; Shrum, G.P.; Connor, D.T.; Dyer, R.D.; Schrier, <lb/>D.J.: Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-<lb/>lipoxygenase and cyclooxygenase inhibitors. J. Med. Chem. 35, <lb/>3691-3698 (1992) <lb/>48. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cruz-Lopez, O.; <lb/>Preti, D.; Tabrizi, M.A.; Fruttarolo, F.; Heilmann, F.; Bermejo, J.; <lb/>Estevez, F.: Hybrid molecules containing benzo[4,5]imidazo[1,2-<lb/>d][1,2,4]thiadiazole and α-bromoacryloyl moieties as potent apop-<lb/>tosis inducers on human myeloid leukaemia cells. Bioorg. Med. <lb/>Chem. Lett. 17, 2844-2848 (2007) <lb/>49. Harai, R.; Sakamoto, K.; Hisamichi, H.; Nagano, N.: Struc-<lb/>ture-activity relationships of cephalosporins having a (dimethyl <lb/>isoxazolidi nio) vinyl moiety at their 3-position. J. Antibiot. 49, <lb/>1162-1171 (1996) <lb/>50. Kharimian, K.; Tam, T.F.; Leung-Toung, R.C.; Li, W.: Thiadiazole <lb/>compounds useful as inhibitors of hb/kb atpase. PCT Int. Appl. <lb/>WO9951584A1 (1999). <lb/>51. Kohara, Y.; Kubo, K.; Imamiya, E.; Wada, T.; Inada, Y.; Naka, <lb/>T.: Synthesis and angiotensin II receptor antagonistic activities <lb/>of benzimidazole derivatives bearing acidic heterocycles as novel <lb/>tetrazole bioisosteres. J. Med. Chem. 39, 5228-5235 (1996) <lb/>52. Leung-Toung, R.; Wodzinska, J.; Li, W.; Lowrie, J.; Kukreja, R.; <lb/>Desilets, D.; Karimian, K.; Tam, T.F.: 1,2,4-thiadiazole: a novel <lb/>cathepsin B inhibitor. Bioorg. Med. Chem. 11, 5529-5537 (2003) <lb/>53. Castro, A.; Castano, T.; Encinas, A.; Porcal, W.; Gil, C.: Advances <lb/>in the synthesis and recent therapeutic applications of 1,2,4-<lb/>thiadiazole heterocycles. Bioorg. Med. Chem. 14, 1644-1652 <lb/>(2006) <lb/>54. Johnstone, C.; Mckerrecher, D.; Pike, K.G.; Waring, M.J.: Het-<lb/>eroaryl benzamide derivatives for use as Glk activators in the <lb/>treatment of diabetes. PCT Int. Appl. WO2005121110A1 (2005). <lb/>55. van den Nieuwendijk, A.M.C.H.; Pietra, D.; Heitman, L.; Gob-<lb/>lyos, A.; Ijzerman, A.P.: Synthesis and biological evaluation of <lb/>2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of <lb/>adenosine receptors. J. Med. Chem. 47, 663-672 (2004) <lb/>56. Mayhoub, A.S.; Marler, L.; Kondratyuk, T.P.; Park, E.J.; Pezzuto, <lb/>J.M.; Cushman, M.C.: Optimizing thiadiazole analogues of resver-<lb/>atrol versus three chemopreventive targets. Bioorg. Med. Chem. 20, <lb/>510-520 (2012) <lb/>57. Kumar, D.; Kumar, N.M.; Chang, K.H.; Gupta, R.; Shah, K.: <lb/>Synthesis and in vitro anticancer activity of 3,5-bis(indolyl)-1,2,4-<lb/>thiadiazoles. Bioorg. Med. Chem. Lett. 21, 5897-5900 (2011) <lb/></listBibl>

			123 


	</text>
</tei>